Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477).
Claudio A
CA
Oton
Fernando
F
Oton
D001918:Brachytherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D010165:Palladium / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012016:Reference Values; D012062:Relative Biological Effectiveness; D012306:Risk
D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium; D017430:Prostate-Specific Antigen